Literature DB >> 26691420

Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality.

Y Inoue1,2, S Fuji1,2, R Tanosaki3, T Fukuda1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26691420     DOI： 10.1038/bmt.2015.315

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.

Authors:  Takashi Ishida; Tatsuro Joh; Naokuni Uike; Kazuhito Yamamoto; Atae Utsunomiya; Shinichiro Yoshida; Yoshio Saburi; Toshihiro Miyamoto; Shigeki Takemoto; Hitoshi Suzushima; Kunihiro Tsukasaki; Kisato Nosaka; Hiroshi Fujiwara; Kenji Ishitsuka; Hiroshi Inagaki; Michinori Ogura; Shiro Akinaga; Masao Tomonaga; Kensei Tobinai; Ryuzo Ueda
Journal:  J Clin Oncol       Date:  2012-02-06       Impact factor: 44.544

2.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

3.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.

Authors:  Patricia A Taylor; Christopher J Lees; Bruce R Blazar
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

4.  Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

Authors:  Kazuhito Yamamoto; Atae Utsunomiya; Kensei Tobinai; Kunihiro Tsukasaki; Naokuni Uike; Kimiharu Uozumi; Kazunari Yamaguchi; Yasuaki Yamada; Shuichi Hanada; Kazuo Tamura; Shigeo Nakamura; Hiroshi Inagaki; Koichi Ohshima; Hitoshi Kiyoi; Takashi Ishida; Kouji Matsushima; Shiro Akinaga; Michinori Ogura; Masao Tomonaga; Ryuzo Ueda
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

Review 5.  Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation.

Authors:  Masao Matsuoka; Kuan-Teh Jeang
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

6.  Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A).

Authors:  Takuya Fukushima; Shogo Nomura; Masanori Shimoyama; Taro Shibata; Yoshitaka Imaizumi; Yoshiyuki Moriuchi; Takeaki Tomoyose; Kimiharu Uozumi; Yukio Kobayashi; Noriyasu Fukushima; Atae Utsunomiya; Mitsutoshi Tara; Kisato Nosaka; Michihiro Hidaka; Naokuni Uike; Shinichiro Yoshida; Kazuo Tamura; Kenji Ishitsuka; Mitsutoshi Kurosawa; Masanobu Nakata; Haruhiko Fukuda; Tomomitsu Hotta; Kensei Tobinai; Kunihiro Tsukasaki
Journal:  Br J Haematol       Date:  2014-06-14       Impact factor: 6.998

7.  VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.

Authors:  Kunihiro Tsukasaki; Atae Utsunomiya; Haruhiko Fukuda; Taro Shibata; Takuya Fukushima; Yoshifusa Takatsuka; Shuichi Ikeda; Masato Masuda; Haruhisa Nagoshi; Ryuzo Ueda; Kazuo Tamura; Masayuki Sano; Saburo Momita; Kazunari Yamaguchi; Fumio Kawano; Shuichi Hanada; Kensei Tobinai; Masanori Shimoyama; Tomomitsu Hotta; Masao Tomonaga
Journal:  J Clin Oncol       Date:  2007-10-29       Impact factor: 44.544

Review 8.  Regulatory T cells in allogeneic stem cell transplantation.

Authors:  Maria Michael; Avichai Shimoni; Arnon Nagler
Journal:  Clin Dev Immunol       Date:  2013-05-08

9.  Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Petra Hoffmann; Joerg Ermann; Matthias Edinger; C Garrison Fathman; Samuel Strober
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

10.  CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease.

Authors:  José L Cohen; Aurélie Trenado; Douglas Vasey; David Klatzmann; Benoît L Salomon
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307
  10 in total
  8 in total

Review 1.  Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma.

Authors:  Shigeo Fuji; Takero Shindo
Journal:  Stem Cell Investig       Date:  2016-10-31

Review 2.  Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas.

Authors:  Silvana Novelli; Anna Monter; M Pilar García-Muret; Rodrigo Martino; Javier Briones; Jorge Sierra
Journal:  Int J Hematol       Date:  2019-07-17       Impact factor: 2.490

3.  Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  Blood       Date:  2016-03-18       Impact factor: 22.113

Review 4.  Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant?

Authors:  E H Phillips; A Hodson; O Hermine; A Bazarbachi; K Cwynarski
Journal:  Bone Marrow Transplant       Date:  2016-09-12       Impact factor: 5.483

5.  Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.

Authors:  Kenji Ishitsuka; Satoshi Yurimoto; Kouichi Kawamura; Yukie Tsuji; Manabu Iwabuchi; Takeshi Takahashi; Kensei Tobinai
Journal:  Int J Hematol       Date:  2017-06-09       Impact factor: 2.319

6.  HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab.

Authors:  Makoto Hirosawa; Takehiro Higashi; Atsushi Iwashige; Takahiro Yamaguchi; Junichi Tsukada
Journal:  Ann Hematol       Date:  2016-10-21       Impact factor: 3.673

7.  Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia/lymphoma patients in non-complete remission.

Authors:  Makoto Hirosawa; Takahiro Yamaguchi; Aya Tanaka; Yoshihiko Kominato; Takehiro Higashi; Hiroaki Morimoto; Junichi Tsukada
Journal:  Ann Hematol       Date:  2020-01-31       Impact factor: 3.673

8.  Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases.

Authors:  Yukie Tsubokura; Atsushi Satake; Masaaki Hotta; Hideaki Yoshimura; Shinya Fujita; Yoshiko Azuma; Takahisa Nakanishi; Aya Nakaya; Tomoki Ito; Kazuyoshi Ishii; Shosaku Nomura
Journal:  Int J Hematol       Date:  2016-08-29       Impact factor: 2.319
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.